Innovation Pharmaceuticals Inc 's ROA from the first quarter of 2024 to the first quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Innovation Pharmaceuticals Inc 's ROA in the first quarter of 2024?
Innovation Pharmaceuticals Inc recorded a cumulative net loss of $-3 million during 12 months ending in the first quarter of 2024, resulting in a negative return on assets (ROA) of -35.06%.

However, within the Healthcare sector 519 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2023 quarter, so far to 4193, from total ROA ranking in the fourth quarter of 2023 at 4356.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2023) I. Quarter	(Jun 30 2023) IV. Quarter	(Mar 31 2023) III. Quarter	(Dec 31 2022) II. Quarter	(Sep 30 2022) I. Quarter
Y / Y Total Assets Change	-17.89 %	-37.2 %	-39.8 %	-33.49 %	-36.61 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-3	-3	-4	-5	-6
Return On Assets (TTM)	-35.06 %	-40.15 %	-46.44 %	-48.93 %	-57.72 %
CTIX's Total Ranking	# 4193	# 4356	# 4642	# 5452	# 4967
Total Assets (TTM) in million	8	7	7	9	9
Seq. Total Assets Change	17.63 %	-7.12 %	-19.25 %	-6.93 %	-10.03 %
Seq. Net Income Change	-	-	-	-	-

CTIX's 5 Years Annual ROA >> Back to CTIX Management Effectiveness >> Compare CTIX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 215
Sector	# 520
Overall	# 4119

Return On Assets Statistics
High	Average	Low
-33.95 %	-120.62 %	-275.62 %
(Sep 30 2023)		(Jun 30 2013)

Financial Statements
Innovation Pharmaceuticals Inc 's Assets	$ 8 million	CTIX's Balance sheet
Innovation Pharmaceuticals Inc 's Income	$ -1 million	Quarterly CTIX's Income Statement
CTIX's Income by Division		See CTIX's Income by Division

Annual Return On Assets	(Jun 30 2023) FY 2023	(Jun 30 2022) FY 2022	(Jun 30 2021) FY 2021	(Jun 30 2020) FY 2020	(Jun 30 2019) FY 2019
Y / Y Total Assets Change	-37.2 %	-27.41 %	54.62 %	128.57 %	-38.14 %
Total Assets in million	7	10	14	9	4
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-3	-7	-14	-7	-9
Annual Return On Assets	-48.6 %	-67.84 %	-97.01 %	-71.89 %	-214.56 %

CTIX's 5 Years Annual ROA >> Back to CTIX Management Effectiveness >> Compare CTIX ROA to its Competitors

More Return On Assets Ratios
CTIX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CTIX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CTIX's Competitors
Subscribers only: Roa for Innovation Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for CTIX's Customers

You may also want to know
CTIX's Roi	CTIX's Inventory Turnover Ratio	CTIX's Growth Rates	CTIX's Dividend Comparisons
	CTIX's Profitability Ratios	CTIX's Asset Turnover Ratio	CTIX's Dividend Growth
CTIX's Roe	CTIX's Valuation Ratios	CTIX's Financial Strength Ratios	CTIX's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2023, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:11:07+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.